All Sauce from Weekly Gravy:

Smoking can’t explain why women are more at risk for COPD, a new study says. Women are about 50% more likely than men to develop COPD even though they are less likely to smoke, researchers reported May 8 in the journal BMJ Open Respiratory Research. Smoking tobacco is the main cause of COPD, the umbrella term for chronic breathing problems like emphysema and bronchitis, researchers say. But the COPD rate is higher among women than men, even though women don’t smoke as much as men, results show. The results refute the notion that women are more vulnerable to tobacco smoke than men, which had previously been floated to explain why more women suffer COPD, researchers said. “The higher risk of COPD in women was not explained by higher susceptibility to cigarette smoke as measured by either smoking status or pack-year exposure,” wrote a team led by Dr. Alexander Steinberg, an assistant professor of clinical practice at the University of Washington in Seattle. “In fact, women had a nearly identical increase in risk of COPD for every 10 pack-years of cigarette use when compared with men,” researchers wrote. Pack-years measure how much a person has smoked by multiplying the packs smoked per day by the number of years a person has smoked. “This then begs the important question of what is driving high rates of COPD…  read on >  read on >

Smoking can’t explain why women are more at risk for COPD, a new study says. Women are about 50% more likely than men to develop COPD even though they are less likely to smoke, researchers reported May 8 in the journal BMJ Open Respiratory Research. Smoking tobacco is the main cause of COPD, the umbrella term for chronic breathing problems like emphysema and bronchitis, researchers say. But the COPD rate is higher among women than men, even though women don’t smoke as much as men, results show. The results refute the notion that women are more vulnerable to tobacco smoke than men, which had previously been floated to explain why more women suffer COPD, researchers said. “The higher risk of COPD in women was not explained by higher susceptibility to cigarette smoke as measured by either smoking status or pack-year exposure,” wrote a team led by Dr. Alexander Steinberg, an assistant professor of clinical practice at the University of Washington in Seattle. “In fact, women had a nearly identical increase in risk of COPD for every 10 pack-years of cigarette use when compared with men,” researchers wrote. Pack-years measure how much a person has smoked by multiplying the packs smoked per day by the number of years a person has smoked. “This then begs the important question of what is driving high rates of COPD…  read on >  read on >

Women with common autoimmune inflammatory diseases are more likely than men to die from heart disease, a new study says. Women with rheumatoid arthritis, lupus or systemic sclerosis have a 50% higher heart disease-related death rate than men, researchers reported May 5 in the journal Circulation: Cardiovascular Quality and Outcomes. “Our study highlights the significant burden of cardiovascular disease in patients with immune-mediated inflammatory diseases, which disproportionately affect women,” said senior researcher Dr. Heba Wassif, director of cardio-rheumatology at the Cleveland Clinic. “It is critical to screen for and address cardiovascular risk factors early, at the time of diagnosis and periodically thereafter,” she said in a news release. Women are two to three times more likely than men to develop rheumatoid arthritis, and about nine times more likely to develop lupus, researchers said in background notes. Systemic sclerosis also is more common among women than men, researchers said. That autoimmune disease involves the tightening and hardening of skin, potentially affecting the digestive tract, blood vessels and internal organs. For the study, researchers analyzed data for more than 127,000 heart disease-related deaths among more than 281,000 deaths associated with the three common autoimmune diseases between 1999 and 2020. Overall, heart disease deaths declined for people with these autoimmune disorders, from 3.9 to 2.1 per 100,000 in women and from 1.7 to 1.2 per 100,000 in men…  read on >  read on >

Women with common autoimmune inflammatory diseases are more likely than men to die from heart disease, a new study says. Women with rheumatoid arthritis, lupus or systemic sclerosis have a 50% higher heart disease-related death rate than men, researchers reported May 5 in the journal Circulation: Cardiovascular Quality and Outcomes. “Our study highlights the significant burden of cardiovascular disease in patients with immune-mediated inflammatory diseases, which disproportionately affect women,” said senior researcher Dr. Heba Wassif, director of cardio-rheumatology at the Cleveland Clinic. “It is critical to screen for and address cardiovascular risk factors early, at the time of diagnosis and periodically thereafter,” she said in a news release. Women are two to three times more likely than men to develop rheumatoid arthritis, and about nine times more likely to develop lupus, researchers said in background notes. Systemic sclerosis also is more common among women than men, researchers said. That autoimmune disease involves the tightening and hardening of skin, potentially affecting the digestive tract, blood vessels and internal organs. For the study, researchers analyzed data for more than 127,000 heart disease-related deaths among more than 281,000 deaths associated with the three common autoimmune diseases between 1999 and 2020. Overall, heart disease deaths declined for people with these autoimmune disorders, from 3.9 to 2.1 per 100,000 in women and from 1.7 to 1.2 per 100,000 in men…  read on >  read on >

A new drug combo lowers “bad” LDL cholesterol for people whose levels remain high even after taking statins. The new pill pairs a new drug called obicetrapib with an existing one, ezetimibe. In a Phase 3 clinical trial, this combo reduced LDL levels by nearly 49% over about three months, according to Cleveland Clinic researchers.  The results were presented Wednesday at the European Atherosclerosis Society meeting in Glasgow, Scotland, and simultaneously published in The Lancet. “High LDL is one of the leading risk factors for heart disease, and we have such a poor handle on controlling that risk,” Dr. Corey Bradley, a cardiologist at Columbia University, told NBC News. “Many people have such a high LDL they will require multiple agents to control it.”  The trial included 407 people with an average age of 68. Even though they were taking cholesterol-lowering medications, everyone had LDL levels above 70 mg/dL. Researchers divided participants into four groups: One took the combo pill; two groups took each drug separately; and another group took a placebo. All participants continued their usual cholesterol medications. Dr. Ashish Sarraju, a preventive cardiologist at the Cleveland Clinic, led the study. “We need to give patients and their doctors all the options we can to try to get LDL under control if they are at risk for, or already have, cardiovascular disease,” Sarraju said.…  read on >  read on >

A new drug combo lowers “bad” LDL cholesterol for people whose levels remain high even after taking statins. The new pill pairs a new drug called obicetrapib with an existing one, ezetimibe. In a Phase 3 clinical trial, this combo reduced LDL levels by nearly 49% over about three months, according to Cleveland Clinic researchers.  The results were presented Wednesday at the European Atherosclerosis Society meeting in Glasgow, Scotland, and simultaneously published in The Lancet. “High LDL is one of the leading risk factors for heart disease, and we have such a poor handle on controlling that risk,” Dr. Corey Bradley, a cardiologist at Columbia University, told NBC News. “Many people have such a high LDL they will require multiple agents to control it.”  The trial included 407 people with an average age of 68. Even though they were taking cholesterol-lowering medications, everyone had LDL levels above 70 mg/dL. Researchers divided participants into four groups: One took the combo pill; two groups took each drug separately; and another group took a placebo. All participants continued their usual cholesterol medications. Dr. Ashish Sarraju, a preventive cardiologist at the Cleveland Clinic, led the study. “We need to give patients and their doctors all the options we can to try to get LDL under control if they are at risk for, or already have, cardiovascular disease,” Sarraju said.…  read on >  read on >

Knowing your risk for Alzheimer’s disease can provide peace of mind, but also might contribute to complacency regarding your overall health, a new study says. People who underwent brain scans to learn their Alzheimer’s risk experienced less anxiety, even if the results showed higher risk, researchers reported May 7 in the journal Alzheimer’s & Dementia. However, people’s motivation to maintain lifestyle changes like exercise and eating a healthy diet also declined after they learned their Alzheimer’s risk, whether or not the results indicated higher or lower risk, researchers said. “The results highlight how easily people lose motivation to make lifestyle changes aimed at maintaining cognitive health,” lead researcher Sapir Golan Shekhtman, a doctoral student at the Joseph Sagol Neuroscience Center at the Sheba Medical Center in Israel, said in a news release. “Strategies to sustain these healthy behaviors are crucial.” The new study comes on the heels of an Alzheimer’s Association’s annual report, which found that 4 of 5 Americans want to know in advance if they will develop Alzheimer’s, through easy, rapid testing. For this study, researchers followed nearly 200 healthy adults who underwent imaging scans to check their brain levels of amyloid beta. Toxic amyloid plaques are a hallmark of Alzheimer’s disease. Prior to the scans, participants completed surveys measuring their anxiety, depression, memory concerns and motivation to improve their lifestyle habits. People…  read on >  read on >

Knowing your risk for Alzheimer’s disease can provide peace of mind, but also might contribute to complacency regarding your overall health, a new study says. People who underwent brain scans to learn their Alzheimer’s risk experienced less anxiety, even if the results showed higher risk, researchers reported May 7 in the journal Alzheimer’s & Dementia. However, people’s motivation to maintain lifestyle changes like exercise and eating a healthy diet also declined after they learned their Alzheimer’s risk, whether or not the results indicated higher or lower risk, researchers said. “The results highlight how easily people lose motivation to make lifestyle changes aimed at maintaining cognitive health,” lead researcher Sapir Golan Shekhtman, a doctoral student at the Joseph Sagol Neuroscience Center at the Sheba Medical Center in Israel, said in a news release. “Strategies to sustain these healthy behaviors are crucial.” The new study comes on the heels of an Alzheimer’s Association’s annual report, which found that 4 of 5 Americans want to know in advance if they will develop Alzheimer’s, through easy, rapid testing. For this study, researchers followed nearly 200 healthy adults who underwent imaging scans to check their brain levels of amyloid beta. Toxic amyloid plaques are a hallmark of Alzheimer’s disease. Prior to the scans, participants completed surveys measuring their anxiety, depression, memory concerns and motivation to improve their lifestyle habits. People…  read on >  read on >

The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research. The division oversees vaccines and biologic medicines, including gene therapies, CNN reported. Prasad is a hematologist-oncologist, a specialist in treating cancers of the blood. He has been a vocal critic of the U.S. government’s response to the COVID-19 pandemic. He has questioned school closures, mask mandates and COVID booster shots. He takes over from Dr. Peter Marks, who led the division for 13 years and played a major role in the COVID vaccine rollout. Marks resigned in March, writing in a letter that U.S. health secretary Robert F. Kennedy Jr. did not value science and transparency. FDA Commissioner Dr. Marty Makary praised Prasad’s background, saying he has a “long and distinguished history in medicine” and highlighted his oncology research, according to CNN. Prasad’s appointment comes as the FDA plans to require future vaccines to be tested through placebo-controlled trials. Public health officials are also reconsidering recommendations for COVID vaccines for children — recommendations Prasad has questioned, because kids face lower risks from the virus than older people and those with weakened immune systems. Amid news of his appointment, biotech stocks fell more than 5%. Sarepta Therapeutics, which makes a gene therapy for Duchenne muscular dystrophy, saw…  read on >  read on >